Literature DB >> 10735833

Active surveillance of hepatitis C infection in the UK and Ireland.

D M Gibb1, P E Neave, P A Tookey, M Ramsay, H Harris, K Balogun, D Goldberg, G Mieli-Vergani, D Kelly.   

Abstract

AIM: To investigate the prevalence, distribution, and clinical details of paediatric hepatitis C virus (HCV) infection in the UK and Ireland.
METHODS: Active monthly surveillance questionnaire study coordinated through the British Paediatric Surveillance Unit, to all consultant paediatricians in 1997 and 1998.
RESULTS: A total of 182 HCV infected children were reported from 54 centres and by paediatricians from eight different specialties. In 40 children HCV was acquired through mother to child transmission (MTC children); 142 were infected by contaminated blood products (n = 134), organ transplantation (n = 2), needles (n = 4), or unknown risk factor (n = 2). Intravenous drug use was the risk factor for 35 mothers of MTC children. Twelve children were coinfected with HIV and four with HBV. Recent serum aspartate aminotransferase or alanine aminotransferase values were at least twofold greater than the upper limit of normal in 24 of 152 children; this occurred in five of 11 HIV coinfected children. Liver histology, available in 53 children, showed normal (7%), mild (74%), moderate (17%), or severe (2%) hepatitis. Twenty eight children had received therapy with interferon alfa.
CONCLUSION: Most current paediatric HCV infection in UK and Ireland has been acquired from contaminated blood products, and most children are asymptomatic. There is a need for multicentre trials to inform clinical practice and development of good practice guidelines in this area. Long term follow up of this cohort of HCV infected children is planned to help determine the natural history over the long term of HCV acquired during infancy and childhood.

Entities:  

Mesh:

Year:  2000        PMID: 10735833      PMCID: PMC1718291          DOI: 10.1136/adc.82.4.286

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  20 in total

1.  Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus.

Authors:  F Bortolotti; M Resti; R Giacchino; C Azzari; N Gussetti; C Crivellaro; C Barbera; F Mannelli; L Zancan; A Bertolini
Journal:  J Pediatr       Date:  1997-06       Impact factor: 4.406

Review 2.  Hepatitis C virus six years on.

Authors:  C L van der Poel; H T Cuypers; H W Reesink
Journal:  Lancet       Date:  1994-11-26       Impact factor: 79.321

3.  The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a.

Authors:  K A Harris; C Gilham; P P Mortimer; C G Teo
Journal:  J Med Virol       Date:  1999-06       Impact factor: 2.327

4.  Epidemiology and detection of HIV-1 among pregnant women in the United Kingdom: results from national surveillance 1988-96.

Authors:  A Nicoll; C McGarrigle; A R Brady; A E Ades; P Tookey; T Duong; J Mortimer; S Cliffe; D Goldberg; D Tappin; C Hudson; C Peckham
Journal:  BMJ       Date:  1998-01-24

5.  Use of polymerase chain reaction and antibody tests in the diagnosis of vertically transmitted hepatitis C virus infection.

Authors:  S L Thomas; M L Newell; C S Peckham; A E Ades; A J Hall
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-10       Impact factor: 3.267

6.  Lymphoblastoid interferon alfa treatment in chronic hepatitis C.

Authors:  R Iorio; P Pensati; S Porzio; I Fariello; S Guida; A Vegnente
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

7.  Serologic, virologic, and histologic characteristics of chronic phase hepatitis C virus disease in children infected by transfusion.

Authors:  S Matsuoka; K Tatara; Y Hayabuchi; Y Taguchi; K Mori; H Honda; S Itou; Y Yuasa; Y Kuroda
Journal:  Pediatrics       Date:  1994-12       Impact factor: 7.124

8.  Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.

Authors:  L B Seeff; Z Buskell-Bales; E C Wright; S J Durako; H J Alter; F L Iber; F B Hollinger; G Gitnick; R G Knodell; R P Perrillo
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  Recombinant interferon-alfa therapy in children with chronic hepatitis C.

Authors:  F Bortolotti; R Giacchino; P Vajro; C Barbera; C Crivellaro; A Alberti; G Nebbia; L Zancan; L De Moliner; A Bertolini
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

10.  Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission.

Authors:  J D Spencer; N Latt; P J Beeby; E Collins; J B Saunders; G W McCaughan; Y E Cossart
Journal:  J Viral Hepat       Date:  1997       Impact factor: 3.728

View more
  3 in total

Review 1.  Perinatal hepatitis C virus infection: diagnosis and management.

Authors:  S M Davison; G Mieli-Vergani; J Sira; D A Kelly
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

2.  The impact of mode of acquisition on biological markers of paediatric hepatitis C virus infection.

Authors:  K England; C Thorne; H Harris; M Ramsay; M-L Newell
Journal:  J Viral Hepat       Date:  2011-06-22       Impact factor: 3.728

Review 3.  Viral hepatitis B and C in children.

Authors:  Deirdre Kelly
Journal:  J R Soc Med       Date:  2006-07       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.